Purdue Pharmaceutical Products L.P. v. Novel Laboratories, Inc: Represented Novel Laboratories, Inc., a pharmaceutical company seeking to market a generic version of Intermezzo®. Intermezzo® is a sublingual formulation of zolpidem indicated for middle-of-the-night insomnia. Following a 10-day bench trial, the judge found in favor of our client, ruling the asserted claims of all three patents invalid for obviousness. The Federal Circuit confirmed the invalidity findings in a summary affirmance.
Prior- art searcher for In re Certain Flash Memory Controllers, Drives, Memory Cards and Media Players and Products Containing Same where the ITC determined that claim 8 of U.S. Patent Number 7,137,011 was invalid for obviousness. (As a Science Advisor at Robins Kaplan LLP)